These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 1794028)

  • 1. Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging.
    Clissold SP; Fitton A; Chrisp P
    Drugs Aging; 1991; 1(5):405-23. PubMed ID: 1794028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Calcitonins and osteoporosis.
    Gennari C; Agnusdei D
    Br J Clin Pract; 1994; 48(4):196-200. PubMed ID: 7917799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.
    Plosker GL; McTavish D
    Drugs Aging; 1996 May; 8(5):378-400. PubMed ID: 8935399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salmon calcitonin: a review of current and future therapeutic indications.
    Chesnut CH; Azria M; Silverman S; Engelhardt M; Olson M; Mindeholm L
    Osteoporos Int; 2008 Apr; 19(4):479-91. PubMed ID: 18071651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.
    Drugs R D; 2004; 5(2):90-3. PubMed ID: 15293868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcitonins: newer routes of delivery.
    Reginster JY
    Osteoporos Int; 1993; 3 Suppl 2():S3-6; discussion S6-7. PubMed ID: 8481597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Calcitonin therapy in osteoporosis.
    Muñoz-Torres M; Alonso G; Raya MP
    Treat Endocrinol; 2004; 3(2):117-32. PubMed ID: 15743107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.
    Gennari C; Nuti R; Agnusdei D; Camporeale A; Martini G
    Drug Saf; 1994 Sep; 11(3):179-95. PubMed ID: 7811400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future horizons for calcitonin: a U.S. perspective.
    Carstens JH; Feinblatt JD
    Calcif Tissue Int; 1991; 49 Suppl 2():S2-6. PubMed ID: 1933616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of Paget's disease of bone with salmon calcitonin nasal spray.
    Gagel RF; Logan C; Mallette LE
    J Am Geriatr Soc; 1988 Nov; 36(11):1010-4. PubMed ID: 3171038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal and intramuscular human calcitonin in female osteoporosis and in Paget's disease of bones: a pilot study.
    Pontiroli AE; Pajetta E; Calderara A; Alberetto M; Pozza G; Manganelli V; Resmini G; Tessari L; Maresca V
    J Endocrinol Invest; 1991 Jan; 14(1):47-51. PubMed ID: 1646250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intranasal salmon calcitonin treatment of Paget's disease of bone. Results in nine patients.
    D'Agostino HR; Barnett CA; Zielinski XJ; Gordan GS
    Clin Orthop Relat Res; 1988 May; (230):223-8. PubMed ID: 3365896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the acute biological action of injectable salmon calcitonin and an injectable and oral calcitonin analogue.
    Devogelaer JP; Azria M; Attinger M; Abbiati G; Castiglioni C; Nagant de Deuxchaisnes C
    Calcif Tissue Int; 1994 Jul; 55(1):71-3. PubMed ID: 7922793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Paget's disease of bone with a combination of intranasal salmon calcitonin and oral calcium and thiazide.
    Evans RA; Somers NM; Dunstan CR; Hills E; Evans M
    Calcif Tissue Int; 1991 Sep; 49(3):164-7. PubMed ID: 1933580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of salmon calcitonin in Paget's disease of bone.
    Singer FR
    Calcif Tissue Int; 1991; 49 Suppl 2():S7-8. PubMed ID: 1933617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin.
    Silverman SL
    Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the acute effects of subcutaneous and intranasal calcitonin.
    O'Doherty DP; Bickerstaff DR; McCloskey EV; Atkins R; Hamdy NA; Kanis JA
    Clin Sci (Lond); 1990 Feb; 78(2):215-9. PubMed ID: 2155751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hypocalcemia induced in patients with Paget's disease by nasal salmon calcitonin. Effects of anti-calcitonin salmine antibodies].
    Reginster JY; Almer S; Gaspar S; Albert A; Deroisy R; Franchimont P
    Rev Rhum Mal Osteoartic; 1989 Jun; 56(7):563-7. PubMed ID: 2756322
    [No Abstract]   [Full Text] [Related]  

  • 20. [Calcitonin nasal spray for Paget's disease of the bone].
    Luboshitzky R; Bar-Shalom R
    Harefuah; 1995 Mar; 128(6):358-62, 399. PubMed ID: 7750816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.